Last Updated: November 16, 2026

Patent: 8,895,033

« Back to Dashboard


Summary for Patent: 8,895,033
Title:Sustained release formulations using non-aqueous carriers
Abstract: The disclosure provides one-component, injectable, sustained release formulations which comprise microspheres containing active pharmaceutical ingredients (e.g., exenatide), wherein the microspheres are suspended in a non-aqueous carrier. The non-aqueous carrier can be an oil, a fractionated oil, triglycerides, diglycerides, monoglycerides, propylene glycol fatty acid diesters, and the like. The formulations offer distinct advantages of long shelf life for the stability and potency of the formulation and sustained release of active pharmaceutical ingredients to reduce the frequency of medication dosing and to increase patient compliance.
Inventor(s): Houchin; Mary L. (Rockville, MD), Lee; Robin H. (San Diego, CA), Qi; Hong (San Diego, CA), Oehrtman; Greg (San Diego, CA), Jennings; Robert N. (San Diego, CA), Coleman; Scott H. (San Diego, CA)
Assignee: Amylin Pharmaceuticals, LLC (San Diego, CA) AstraZeneca Pharmaceuticals LP (Wilmington, DE)
Application Number:13/060,225
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

United States Patent 8,895,033: Claim Scope, Patent Strength, Exclusivity and Competitive Landscape

United States Patent 8,895,033 protects a ready-to-use injectable suspension containing biodegradable polymer microspheres dispersed in a medium-chain triglyceride carrier. Its broadest independent claim requires four core elements: a pre-mixed injectable product, a nonaqueous triglyceride carrier, biodegradable polymer microspheres containing an active ingredient, and a narrowly defined C6-C12 fatty-acid profile. The patent also contains narrower claim coverage for PLGA microspheres, sucrose, exenatide, a 1:1 lactide:glycolide ratio, therapeutic methods and injection-device kits.

The patent is most relevant to long-acting injectable formulations of exenatide and other peptide or small-molecule APIs. It does not automatically cover every exenatide microsphere product. A competing product must satisfy the carrier composition, microsphere and pre-mixing limitations to fall within the independent formulation claims.

What does United States Patent 8,895,033 protect?

The patent protects a formulation architecture rather than exenatide as a molecule. The central combination is:

Required element Claim requirement
Product type Manufactured, pre-mixed formulation for injection
Continuous phase Pharmaceutically acceptable nonaqueous carrier
Carrier chemistry One or more triglycerides
C6 fatty acids 0-2 wt%
C8 fatty acids 50-65 wt%
C10 fatty acids 30-45 wt%
C12 fatty acids 0-2 wt%
Dispersed phase Microspheres
Microsphere polymer Biocompatible, biodegradable polymer
Active ingredient Broad Markush group, including exenatide
Optional excipient Sugar, sugar alcohol or other listed excipient
Optional formulation limitation No gel-forming agent
Delivery format Vial, cartridge or pen injector under the kit claims

The fatty-acid profile is a major claim boundary. It effectively describes a medium-chain triglyceride system dominated by octanoic and decanoic acid residues. A carrier outside the claimed C8/C10 ranges could avoid literal infringement even if the product otherwise uses PLGA microspheres and exenatide.

How are the claims structured?

Claims 1-8: broad formulation claims

Claim 1 is the primary composition claim. It covers a suspension of biodegradable microspheres in a specified triglyceride carrier.

Claim 2 adds a pharmaceutically acceptable excipient. Claim 3 limits the excipient to a sugar or sugar alcohol and adds an antioxidant or preservative. Claim 4 lists specific excipients, including sucrose, trehalose, mannitol, sorbitol, parabens, tocopherol, ascorbate and related materials.

Claim 5 excludes a gel-forming agent. This negative limitation may be commercially significant because it distinguishes a free-flowing suspension from in situ gel systems or viscous depot formulations.

Claim 6 contains a broad polymer Markush group. It includes:

  • Polylactide and polyglycolide;
  • Poly(lactide-co-glycolide), commonly known as PLGA;
  • Polycaprolactone;
  • Polycarbonates;
  • Polyesteramides;
  • Polyanhydrides;
  • Polyamino acids;
  • Polyorthoesters;
  • Polycyanoacrylates;
  • Polyurethanes; and
  • Related copolymers.

Claim 7 covers a wide API class. The list includes GLP-1 receptor agonists, exenatide, pramlintide, insulin, glucagon-related agents, metreleptin, salicylates, minocycline and small-molecule compounds.

Claim 8 limits microsphere concentration to 10-500 mg/mL, or 20-200 mg/mL. The alternative ranges provide fallback positions but also create measurable design-around opportunities.

Claims 9-10: method-of-use protection

Claim 9 covers administration of the claim 1 formulation for metabolic and gastrointestinal indications, including:

  • Diabetes;
  • Hyperglycemia;
  • Impaired glucose tolerance;
  • Obesity and overweight;
  • Fatty liver disease;
  • Non-alcoholic steatohepatitis;
  • Appetite reduction;
  • Delayed gastric emptying;
  • Lowered plasma glucagon; and
  • Insulin-release stimulation.

Claim 10 adds coadministration with metformin, a sulfonylurea or a thiazolidinedione.

These method claims are narrower than a conventional exenatide method claim because they require use of the specific formulation in claim 1. They should not be treated as independent protection for exenatide therapy generally.

Claims 11-12: kit and device claims

Claims 11 and 12 cover a container holding the formulation with instructions for use. The container may be a:

  • Single-dose or multidose pen injector;
  • Single-dose or multidose vial; or
  • Single-dose or multidose cartridge.

These claims extend the patent beyond bulk formulation manufacture. A commercial product could face separate infringement exposure from its packaging or delivery system if the formulation and container limitations are satisfied.

Claims 13-18: exenatide and PLGA fallback claims

Claim 13 is the most commercially specific formulation claim. It requires:

  • The claimed medium-chain triglyceride carrier;
  • PLGA microspheres;
  • About 2 wt% sucrose;
  • About 5 wt% exenatide; and
  • Approximately a 1:1 lactide:glycolide ratio.

Claims 14-18 create narrower combinations involving PLGA, exenatide, approximately 5 wt% exenatide and sucrose.

The claim language creates a strong technical fingerprint. A product using exenatide-loaded 1:1 PLGA microspheres in a medium-chain triglyceride carrier with approximately 2% sucrose and 5% peptide loading would be substantially closer to the patent than a conventional aqueous exenatide microsphere suspension.

How strong is the patent estate for US 8,895,033?

The patent has meaningful breadth at the platform level but its enforceability depends heavily on claim construction and proof of the carrier composition.

Strength factor Assessment
Formulation concept Strong if a product uses a pre-mixed nonaqueous suspension
API coverage Broad, because claim 1 is not limited to exenatide
Polymer coverage Broad Markush group, subject to written-description and enablement scrutiny
Carrier limitation Narrow and analytically measurable
Exenatide fallback claims Commercially focused but easier to design around
Method claims Dependent on use of the claim 1 formulation
Kit claims Potentially useful against integrated commercial products
Manufacturing protection Limited; the supplied claims do not directly claim microsphere manufacture
Regulatory linkage Product-specific and not automatically linked to FDA approval
Design-around risk Material

Likely validity pressure points

The principal validity issues are predictable for this type of formulation patent.

First, the polymer Markush language is extensive. A challenger could argue that the specification does not enable the full range of listed polymers, APIs and formulation combinations without undue experimentation. The risk is greatest where the claims cover polymer classes that have materially different degradation, loading and release characteristics.

Second, prior-art references may disclose biodegradable microspheres in triglyceride vehicles, or exenatide microspheres in injectable carriers. The patent's strongest novelty position is likely the specific combination of a pre-mixed suspension and the defined C8/C10 fatty-acid profile.

Third, the claims use approximate terms such as "about 2 wt%" and "about 5 wt%." Courts generally interpret "about" in context, based on the specification, prosecution history and technical variability. Those terms create flexibility but can also generate litigation over analytical tolerances.

Fourth, claim 13 appears to contain unusual dependency and drafting structure. Claims 14-18 refer back to earlier claims while restating elements associated with the narrower exenatide formulation. The prosecution history would be important in determining whether those claims were amended, corrected or narrowed during examination.

When does US 8,895,033 lose exclusivity?

The patent issued on December 2, 2014. Its effective patent term is generally measured as 20 years from the earliest effective nonprovisional or PCT filing date under 35 U.S.C. §154. Public patent records associate the application with a 2009 international filing and an earlier 2008 priority date. On that basis, the nominal expiration is in 2029, subject to patent-term adjustment, patent-term extension and any terminal disclaimer recorded by the USPTO.

Event Date or period
Earliest priority 2008, based on the patent family record
International or non-U.S. filing activity 2009 family period
U.S. grant December 2, 2014
Nominal statutory expiration Approximately 2029
Possible adjustment PTA, PTE or terminal disclaimer must be applied from the USPTO record
Post-expiration status Claims generally cease to block new commercial activity, subject to other unexpired patents

The grant date does not determine expiration. A later continuation, divisional or related patent may expire on a different date, but a later-filed continuation does not ordinarily receive a fresh 20-year term.

What is the Orange Book status of US 8,895,033?

US 8,895,033 should not be assumed to be an Orange Book patent merely because it claims an injectable drug formulation.

The FDA Orange Book lists patents submitted by an NDA holder for an approved drug product, subject to the statutory and regulatory requirements governing drug substance, drug product and method-of-use patents. A patent directed to a platform formulation may be eligible for listing only if it appropriately reads on the approved drug product or an approved use.

The approved Bydureon products historically used exenatide encapsulated in PLGA microspheres, but the commercial presentation involved reconstitution with an aqueous diluent before administration. The FDA-approved product description is therefore materially different from the claimed pre-mixed nonaqueous triglyceride suspension.[2]

The practical conclusion is:

Question Assessment
Does the patent cover exenatide microspheres generally? No
Does it necessarily cover Bydureon? No
Does an aqueous reconstituted product meet the nonaqueous-carrier limitation? Ordinarily no
Is the patent automatically an Orange Book patent? No
Does Orange Book listing determine validity? No
Can an unlisted patent still create litigation risk? Yes, subject to applicable patent law

The FDA Orange Book should be checked by patent number and product NDA for current listing status. Patent listing status can change through delisting, product withdrawal or regulatory corrections.[1]

What patent landscape surrounds exenatide microsphere formulations?

The relevant landscape has three layers.

Exenatide molecule and peptide patents

The exenatide molecule and its therapeutic use are distinct from the formulation claims in US 8,895,033. Older exenatide patents have largely reached the end of their ordinary terms or are no longer the principal barrier to entry. Current risk is more likely to arise from formulation, device, manufacturing and method-of-use patents.

PLGA microsphere patents

PLGA depot patents often claim:

  • Polymer molecular weight;
  • Lactide:glycolide ratios;
  • Particle-size distributions;
  • Encapsulation efficiency;
  • Peptide loading;
  • Release profiles;
  • Residual solvent limits;
  • Microsphere morphology;
  • Aqueous reconstitution systems; and
  • Lyophilization or drying processes.

US 8,895,033 differs from many conventional depot patents because the principal vehicle is a nonaqueous triglyceride carrier and the formulation is pre-mixed before administration.

Approved exenatide products

Bydureon and Bydureon BCise are the most relevant commercial comparators. Their product technology is based on extended-release exenatide microspheres, but the approved products are supplied with or in a system involving an aqueous diluent and reconstitution or suspension before injection.[2,3]

Product or technology Microsphere API Carrier or presentation Relationship to US 8,895,033
Bydureon Exenatide in PLGA microspheres Reconstituted injectable presentation Potentially outside nonaqueous pre-mixed limitation
Bydureon BCise Exenatide extended-release microspheres Single-dose autoinjector presentation Device and formulation analysis required
Claimed platform Broad APIs, including exenatide Pre-mixed triglyceride suspension Direct technical target
Conventional aqueous PLGA depot Peptide or small molecule Aqueous suspension or reconstitution Usually weaker literal overlap

Which companies are challenging or licensing around the patent?

No publicly established Paragraph IV challenge or settlement specific to US 8,895,033 is identified in the supplied record. The absence of a known case does not establish that the patent is unchallenged. A Paragraph IV dispute would generally require an ANDA applicant to identify the patent in its certification and the NDA holder to bring suit within the statutory period.

The more probable commercial risk is not a direct exenatide generic challenge. It is development of an alternative long-acting injectable using:

  • An aqueous rather than nonaqueous vehicle;
  • A different triglyceride fatty-acid distribution;
  • A polymer other than PLGA;
  • A different lactide:glycolide ratio;
  • A microsphere concentration outside the claimed ranges;
  • A separate vial-and-diluent presentation; or
  • A different peptide-loading profile.

A biosimilar analysis is generally inapposite. Exenatide is a chemically synthesized peptide drug, not a biologic approved through the traditional biologics pathway. The principal competitive pathway is therefore generic or hybrid drug development, not a conventional biosimilar pathway.[4]

What generic entry risks exist?

A generic or follow-on developer faces several distinct risks.

Literal infringement risk

The highest risk arises when all measurable elements are present:

  1. The product is supplied pre-mixed;
  2. The continuous phase is a triglyceride-based nonaqueous carrier;
  3. The fatty-acid profile falls within the C6-C12 ranges;
  4. The product contains biodegradable microspheres;
  5. The microspheres contain exenatide or another listed API; and
  6. The product uses the claimed concentration or excipient profile.

Equivalents risk

A product outside a numerical range could still create a doctrine-of-equivalents dispute. The risk is lower where the fatty-acid distribution materially changes suspension stability, injection performance or release behavior. Prosecution-history estoppel could restrict the patentee if the ranges were added to overcome prior art.

Regulatory substitution risk

A product that uses a different presentation may avoid this patent but still require separate FDA work on:

  • Drug-device compatibility;
  • Dose uniformity;
  • In-use stability;
  • Resuspendability;
  • Injection force;
  • Particle-size control;
  • Sterility;
  • Extractables and leachables; and
  • Comparative pharmacokinetics.

Avoiding the patent does not eliminate development risk. It shifts risk to formulation, manufacturing and regulatory validation.

What manufacturing and IP barriers matter most?

The patent claims the final formulation, not every process needed to produce it. A commercial entrant would still need to control:

  • PLGA polymer supply and specifications;
  • Microsphere fabrication;
  • Peptide encapsulation;
  • Residual solvent removal;
  • Sterile processing;
  • Particle-size distribution;
  • Suspension homogeneity;
  • Sedimentation and resuspension;
  • Syringe, cartridge or pen compatibility; and
  • Long-term storage stability.

The carrier limitation is particularly important because triglyceride excipients may vary by supplier, grade and analytical method. Fatty-acid composition should be measured against the total fatty-acid content of the triglycerides, as the claim requires. A label declaration alone may not resolve infringement; batch-specific composition and supplier specifications may be relevant.

How does US 8,895,033 compare with typical depot formulation patents?

Feature US 8,895,033 Typical aqueous PLGA depot patent
Product state Pre-mixed Often reconstituted
Continuous phase Nonaqueous triglyceride Water-based diluent or suspension
Polymer Broad biodegradable polymer group Often PLGA-specific
API Broad Markush group Usually one API or peptide class
Key numerical limitation C8/C10 fatty-acid profile Particle size, loading or release
Device coverage Yes, through kit claims Sometimes
Manufacturing claims Limited in supplied claims Often more developed
Main design-around Change carrier or presentation Change polymer, loading or release profile

Key Takeaways

  • US 8,895,033 is a formulation-platform patent centered on a pre-mixed, nonaqueous triglyceride suspension of biodegradable microspheres.
  • The C8/C10 fatty-acid profile is the central technical limitation and the clearest design-around boundary.
  • The patent covers exenatide through broad and narrow claims but does not cover exenatide or PLGA microspheres generally.
  • Claim 13 is the most commercially specific claim because it combines PLGA, approximately 2% sucrose, approximately 5% exenatide and a 1:1 lactide:glycolide ratio.
  • Bydureon-type aqueous reconstitution technology is technically distinct from the claimed pre-mixed nonaqueous presentation.
  • The nominal patent term reaches approximately 2029, subject to USPTO-recorded term adjustments and related term events.
  • No patent-specific Paragraph IV challenge or settlement is established here.
  • The strongest design-around strategies involve changing the carrier, fatty-acid composition, presentation, polymer composition or formulation concentrations.
  • Manufacturing patents and regulatory barriers may remain important even where a competing product avoids literal infringement.

FAQs

Does US 8,895,033 cover all long-acting exenatide injections?

No. The independent formulation claim requires a pre-mixed nonaqueous triglyceride carrier with a specified fatty-acid profile and biodegradable microspheres.

Can an aqueous exenatide microsphere product infringe this patent?

Usually not literally, because claim 1 requires a pharmaceutically acceptable nonaqueous carrier comprising one or more triglycerides. Other claims or related patents could still be relevant.

Is the 1:1 PLGA ratio required for every claim?

No. It is required by the narrower claims directed to that specific PLGA composition. Claim 1 and several other claims use broader polymer language.

Does the patent protect a pen injector by itself?

No. The kit claims require a container holding the claimed formulation and instructions for use. A pen containing a different formulation would not satisfy those limitations.

Is a follow-on exenatide product a biosimilar?

Generally no. Exenatide products are typically evaluated through the generic or hybrid drug framework rather than the conventional biosimilar pathway.

References

  1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.

  2. U.S. Food and Drug Administration. (2023). Bydureon prescribing information. AstraZeneca Pharmaceuticals LP.

  3. U.S. Food and Drug Administration. (2023). Bydureon BCise prescribing information. AstraZeneca Pharmaceuticals LP.

  4. U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biologic products. FDA.

  5. United States Patent and Trademark Office. (2014). United States Patent No. 8,895,033, pre-mixed formulations for injection.

  6. United States Code, 35 U.S.C. §§ 154, 271, 355.

More… ↓

⤷  Start Trial

Details for Patent 8,895,033

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Chiesi Farmaceutici S.p.a. MYALEPT metreleptin For Injection 125390 February 24, 2014 ⤷  Start Trial 2029-09-04
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.